RadioMedix, Inc. is a clinical-stage biotechnology company focused on discovery and manufacturing of innovative radiopharmaceuticals.
RadioMedix, Inc. is a clinical-stage biotechnology company, focused on innovative radiopharmaceuticals for diagnosis, monitoring, and treatment of Cancer using Targeted Alpha Therapy (TAT) . The company has a drug discovery center for early probe development, a pre-clinical core facility for in vitro and in vivo evaluation of radiopharmaceuticals, and a 27,500 SQF cGMP manufacturing facility (the 'SPICA' center) with a full analytical suite for Phase I-III clinical trials, and large-scale post-approval commercial manufacturing. RadioMedix offers full CDMO services to study sponsors seeking manufacturing capacity and logistcal expertise.
RadioMedix received FDA approval for it’s first PET diagnostic radiopharmaceutical , Cu-64-DOTATATE (Detectnet™ ) in September of 2020 and continues to develop our platform of TAT radiopharmaceuticals using Pb-212 and Ac-225 for unmet needs in oncology such as brain tumors, pancreatic cancer and prostate cancer. RadioMedix’s lead TAT compound is Pb-212 -DOTAMTATE. This drug is completing phase II trial with exemplary results in patients with somatostatin expressing neuroendocrine cancers. To learn more, visit www.radiomedix.com.
Brands: AlphaMedix, Detectnet